191 related articles for article (PubMed ID: 20599499)
1. A population pharmacokinetic evaluation of the influence of CYP2D6 genotype on risperidone metabolism in patients with acute episode of schizophrenia.
Locatelli I; Kastelic M; Koprivsek J; Kores-Plesnicar B; Mrhar A; Dolzan V; Grabnar I
Eur J Pharm Sci; 2010 Oct; 41(2):289-98. PubMed ID: 20599499
[TBL] [Abstract][Full Text] [Related]
2. Effects of the CYP2D6*10 alleles and co-medication with CYP2D6-dependent drugs on risperidone metabolism in patients with schizophrenia.
Yagihashi T; Mizuno M; Chino B; Sato Y; Sakuma K; Takebayashi T; Takao T; Kosaki K
Hum Psychopharmacol; 2009 Jun; 24(4):301-8. PubMed ID: 19387994
[TBL] [Abstract][Full Text] [Related]
3. A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A.
Bork JA; Rogers T; Wedlund PJ; de Leon J
J Clin Psychiatry; 1999 Jul; 60(7):469-76. PubMed ID: 10453802
[TBL] [Abstract][Full Text] [Related]
4. Effects of CYP2D6 genotype on the pharmacokinetics, pharmacodynamics, and safety of risperidone in healthy volunteers.
Novalbos J; López-Rodríguez R; Román M; Gallego-Sandín S; Ochoa D; Abad-Santos F
J Clin Psychopharmacol; 2010 Oct; 30(5):504-11. PubMed ID: 20814331
[TBL] [Abstract][Full Text] [Related]
5. Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients.
Jung SM; Kim KA; Cho HK; Jung IG; Park PW; Byun WT; Park JY
Clin Pharmacol Ther; 2005 Nov; 78(5):520-8. PubMed ID: 16321618
[TBL] [Abstract][Full Text] [Related]
6. Impact of CYP2D6 Polymorphism on Steady-State Plasma Levels of Risperidone and 9-Hydroxyrisperidone in Thai Children and Adolescents with Autism Spectrum Disorder.
Vanwong N; Ngamsamut N; Medhasi S; Puangpetch A; Chamnanphon M; Tan-Kam T; Hongkaew Y; Limsila P; Sukasem C
J Child Adolesc Psychopharmacol; 2017 Mar; 27(2):185-191. PubMed ID: 26780783
[TBL] [Abstract][Full Text] [Related]
7. A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels.
Leon Jd; Susce MT; Pan RM; Wedlund PJ; Orrego ML; Diaz FJ
Pharmacopsychiatry; 2007 May; 40(3):93-102. PubMed ID: 17541883
[TBL] [Abstract][Full Text] [Related]
8. Relevance of CYP2D6 variability in first-episode schizophrenia patients treated with risperidone.
Barteček R; Juřica J; Zrůstová J; Kašpárek T; Pindurová E; Žourková A
Neuro Endocrinol Lett; 2012; 33(2):236-44. PubMed ID: 22592207
[TBL] [Abstract][Full Text] [Related]
9. CYP2D6 Genetic Polymorphisms and Risperidone Pharmacokinetics: A Systematic Review and Meta-analysis.
Zhang L; Brown SJ; Shan Y; Lee AM; Allen JD; Eum S; de Leon J; Bishop JR
Pharmacotherapy; 2020 Jul; 40(7):632-647. PubMed ID: 32519344
[TBL] [Abstract][Full Text] [Related]
10. The role of CYP2D6 and ABCB1 pharmacogenetics in drug-naïve patients with first-episode schizophrenia treated with risperidone.
Jovanović N; Božina N; Lovrić M; Medved V; Jakovljević M; Peleš AM
Eur J Clin Pharmacol; 2010 Nov; 66(11):1109-17. PubMed ID: 20563569
[TBL] [Abstract][Full Text] [Related]
11. Risperidone metabolism in relation to CYP2D6*10 allele in Korean schizophrenic patients.
Roh HK; Kim CE; Chung WG; Park CS; Svensson JO; Bertilsson L
Eur J Clin Pharmacol; 2001 Nov; 57(9):671-5. PubMed ID: 11791898
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension.
Zineh I; Beitelshees AL; Gaedigk A; Walker JR; Pauly DF; Eberst K; Leeder JS; Phillips MS; Gelfand CA; Johnson JA
Clin Pharmacol Ther; 2004 Dec; 76(6):536-44. PubMed ID: 15592325
[TBL] [Abstract][Full Text] [Related]
13. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment.
Plesnicar BK; Zalar B; Breskvar K; Dolzan V
J Psychopharmacol; 2006 Nov; 20(6):829-33. PubMed ID: 16478753
[TBL] [Abstract][Full Text] [Related]
14. Cytochrome P450 2D6 deficiency and its clinical relevance in a patient treated with risperidone.
Köhnke MD; Griese EU; Stösser D; Gaertner I; Barth G
Pharmacopsychiatry; 2002 May; 35(3):116-8. PubMed ID: 12107857
[TBL] [Abstract][Full Text] [Related]
15. Effect of the cytochrome P450 2D6*10 allele on risperidone metabolism in Japanese psychiatric patients.
Suzuki Y; Fukui N; Tsuneyama N; Watanabe J; Ono S; Sugai T; Saito M; Inoue Y; Someya T
Hum Psychopharmacol; 2012 Jan; 27(1):43-6. PubMed ID: 22745940
[TBL] [Abstract][Full Text] [Related]
16. Significant pharmacokinetic interaction between risperidone and carbamazepine: its relationship with CYP2D6 genotypes.
Ono S; Mihara K; Suzuki A; Kondo T; Yasui-Furukori N; Furukori H; de Vries R; Kaneko S
Psychopharmacology (Berl); 2002 Jun; 162(1):50-4. PubMed ID: 12107617
[TBL] [Abstract][Full Text] [Related]
17. Serum prolactin levels, plasma risperidone levels, polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia.
Wang L; Yu L; Zhang AP; Fang C; Du J; Gu NF; Qin SY; Feng GY; Li XW; Xing QH; He L
J Psychopharmacol; 2007 Nov; 21(8):837-42. PubMed ID: 17715206
[TBL] [Abstract][Full Text] [Related]
18. Impact of CYP2D6 genotype on steady-state serum concentrations of risperidone and 9-hydroxyrisperidone in patients using long-acting injectable risperidone.
Hendset M; Molden E; Refsum H; Hermann M
J Clin Psychopharmacol; 2009 Dec; 29(6):537-41. PubMed ID: 19910717
[TBL] [Abstract][Full Text] [Related]
19. Risperidone metabolic ratio as a biomarker of individual CYP2D6 genotype in schizophrenic patients.
Mannheimer B; Holm J; Koukel L; Bertilsson L; Osby U; Eliasson E
Eur J Clin Pharmacol; 2014 Jun; 70(6):695-9. PubMed ID: 24643635
[TBL] [Abstract][Full Text] [Related]
20. Effects of CYP2D6 genotypes on plasma concentrations of risperidone and enantiomers of 9-hydroxyrisperidone in Japanese patients with schizophrenia.
Yasui-Furukori N; Mihara K; Kondo T; Kubota T; Iga T; Takarada Y; De Vries R; Kaneko S; Tateishi T
J Clin Pharmacol; 2003 Feb; 43(2):122-7. PubMed ID: 12616663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
